These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34837321)

  • 21. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
    Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
    J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells.
    Uhl M; Kepp O; Jusforgues-Saklani H; Vicencio JM; Kroemer G; Albert ML
    Cell Death Differ; 2009 Jul; 16(7):991-1005. PubMed ID: 19229247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation.
    Hirosue S; Kourtis IC; van der Vlies AJ; Hubbell JA; Swartz MA
    Vaccine; 2010 Nov; 28(50):7897-906. PubMed ID: 20934457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineered Cell-Membrane-Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity.
    Jiang Y; Krishnan N; Zhou J; Chekuri S; Wei X; Kroll AV; Yu CL; Duan Y; Gao W; Fang RH; Zhang L
    Adv Mater; 2020 Jul; 32(30):e2001808. PubMed ID: 32538494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ.
    Fujii SI; Yamasaki S; Hanada K; Ueda S; Kawamura M; Shimizu K
    Cancer Sci; 2022 Mar; 113(3):864-874. PubMed ID: 34971473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses.
    Liu J; Liu X; Han Y; Zhang J; Liu D; Ma G; Li C; Liu L; Kong D
    ACS Appl Mater Interfaces; 2018 Sep; 10(37):30983-30993. PubMed ID: 30136844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.
    Groh V; Li YQ; Cioca D; Hunder NN; Wang W; Riddell SR; Yee C; Spies T
    Proc Natl Acad Sci U S A; 2005 May; 102(18):6461-6. PubMed ID: 15824323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein.
    Fu Q; Wu Y; Yan F; Wang N; Wang W; Cao X; Wang Y; Wan T
    Cell Mol Immunol; 2011 Sep; 8(5):424-32. PubMed ID: 21785448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B lymphocytes participate in cross-presentation of antigen following gene gun vaccination.
    Hon H; Oran A; Brocker T; Jacob J
    J Immunol; 2005 May; 174(9):5233-42. PubMed ID: 15843519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response.
    Song C; Noh YW; Lim YT
    Int J Nanomedicine; 2016; 11():3753-64. PubMed ID: 27540289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
    Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
    Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.
    Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J
    J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
    Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
    J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquisition and Presentation of Tumor Antigens by Dendritic Cells.
    Bonaccorsi I; Campana S; Morandi B; Ferlazzo G
    Crit Rev Immunol; 2015; 35(5):349-64. PubMed ID: 26853848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.
    Dhodapkar KM; Krasovsky J; Williamson B; Dhodapkar MV
    J Exp Med; 2002 Jan; 195(1):125-33. PubMed ID: 11781371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cells require NIK for CD40-dependent cross-priming of CD8+ T cells.
    Katakam AK; Brightbill H; Franci C; Kung C; Nunez V; Jones C; Peng I; Jeet S; Wu LC; Mellman I; Delamarre L; Austin CD
    Proc Natl Acad Sci U S A; 2015 Nov; 112(47):14664-9. PubMed ID: 26561586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inducing efficient cross-priming using antigen-coated yeast particles.
    Howland SW; Tsuji T; Gnjatic S; Ritter G; Old LJ; Wittrup KD
    J Immunother; 2008 Sep; 31(7):607-19. PubMed ID: 18600183
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Wang Y; Lin YX; Wang J; Qiao SL; Liu YY; Dong WQ; Wang J; An HW; Yang C; Mamuti M; Wang L; Huang B; Wang H
    ACS Nano; 2019 Jul; 13(7):7568-7577. PubMed ID: 31260255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.
    Flinsenberg TW; Compeer EB; Boelens JJ; Boes M
    Clin Exp Immunol; 2011 Jul; 165(1):8-18. PubMed ID: 21561444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective Priming of Herpes Simplex Virus-Specific CD8
    Whitney PG; Makhlouf C; MacLeod B; Ma JZ; Gressier E; Greyer M; Hochheiser K; Bachem A; Zaid A; Voehringer D; Heath WR; Wagle MV; Parish I; Russell TA; Smith SA; Tscharke DC; Gebhardt T; Bedoui S
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.